We understand that a newspaper would find it interesting to report on the human interest angle of someone who grew up on a pig farm who won an award for his invention and who hopes to hire disabled veterans to work on his invention.
But a health story – so categorized by the Chicago Tribune – that includes claims about saving lives, reducing risks to an absolute minimum, and decreasing health care costs – needs to provide some evidence to back up such claims.
This story didn’t deliver that evidence. It was an impressive job of cheerleading, though.
The compelling human interest angle of the story shouldn’t deceive any reader into thinking that this “breakthrough” approach can do what the story claims it can do. Maybe it can. But we urge journalists to take a more evidence-based approach to such claims – even in a human interest story and certainly in one in the health section.
The use of a peripherally-inserted catheter to measure central venous pressures is not new and has been studied for more than a decade (see Crit Care Med 2000 Vol. 28, No. 12). While some would argue that using the arm as an access site is preferable, there are no studies to back up that claim. It might be easier to do and not require the skill level of a neck insertion but the catheter ends up in the same place and shares all of the liabilities of any central venous catheter. (By the way, central venous pressure measurement catheters end up in a blood vessel and not in the heart as described in the story.)
There is no discussion of how much the “breakthrough” approach will cost.
The story states that the catheter:
But there isn’t one piece of data – of evidence – presented in the entire 718-word story. That’s not a short story these days – so there was plenty of space afforded.
There was no discussion of harms in the story. Placing a catheter into the central circulation and measuring pressure is not without the potential for harm. Although the risk of a catastrophic rare neck artery puncture may be avoided with the use of the arm approach, the risks of misplacement and infection may not be reduced.
There was no discussion of evidence – yet the story provides a clue about why.
Late in the story, a doctor is quoted saying that “he wants to test the first 50 catheters” that the inventor can provide.
Does that mean there’s no clinical evidence yet? For an approach that the story says “will save lives…decrease health care costs…reduce risks to an absolute minimum” ???
In reality, the device was approved by the FDA under the assumption that it is not all that different from existing devices commercially available.
Not applicable. There wasn’t really any specific discussion of any condition.
The story at least turns to two physicians who are considering use of the catheter at their hospitals.
Venous heart catheters are mentioned – but no meaningful comparison was made with the new approach – again, because no evidence was provided. It is actually somewhat disingenuous to claim superiority of a new device that was approved by the FDA under a 510K premarket approval process – which is predicated on the assumption that the device is not significantly different than existing devices already on the market.
Not clearly explained. Is anyone using this catheter clinically right now?
Peripherally-inserted central venous catheters for drug and fluid delivery as well as pressure management is not a new concept. This wasn’t discussed at all in the story. While there may be advantages to the use of the arm for access, there are also potential disadvantages. While controversial, some studies have suggested that many patients in shock would benefit from a pulmonary artery catheter (usually inserted in a neck vein) that allows doctors to have a better understanding of a patient’s blood volume and performance of the heart. While a pulmonary artery catheter takes time and skill to place and interpret, the debate about which approach is best is ongoing. This story didn’t reflect the debate – making the inventor’s approach seem like a slam dunk.
Because other sources were quoted, it does not appear that the story relied solely on a news release.
Systematic, Criteria-Driven
Like claiming that the coronavirus vaccines could leave people “magnetized” https://www.washingtonpost.com/politics/2021/12/06/some-doctors-spreading-coronavirus-misinformation-are-being-punished/
Like Michael Corleone of science reporting that @garyschwitzer is (he tries to get out, bullshit disguised as #science #journalism keeps pulling him back in!), he drops this on @nytimes idiocy 🙄 in reporting T1 diabetes "cure"
HT @HealthNewsRevu
https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
A great read on this weekend’s NYT claims of a cure for Type 1.
Cure for Type 1 diabetes? We’ve been down this road before with NY Times https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like